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Although stromal cell-derived factor (SDF)-1a and its receptor CXCR4 are experimentally suggested to be involved in tumorigenicity,
the clinicopathological significance of their expression in human disease is not fully understood. We examined SDF-1a and CXCR4
expression in colorectal cancers (CRCs) and their related lymph nodes (LNs), and investigated its relationship to clinicopathological
features. Specimens of 60 primary CRCs and 27 related LNs were examined immunohistochemically for not only positivity but also
immunostaining patterns for SDF-1a and CXCR4. The relationships between clinicopathological features and SDF-1a or CXCR4
expression were then analysed. Stromal cell-derived factor-1a and CXCR4 expression were significantly associated with LN
metastasis, tumour stage, and survival of CRC patients. Twenty-nine of 47 CXCR4-positive CRCs (61.7%) showed clear CXCR4
immunoreactivity in the nucleus and a weak signal in the cytoplasm (nuclear type), whereas others showed no nuclear
immunoreactivity but a diffuse signal in the cytoplasm and at the plasma membrane (cytomembrane type). Colorectal cancer patients
with nuclear CXCR4 expression showed significantly more frequent LN metastasis than did those with cytomembrane expression.
Colorectal cancer patients with nuclear CXCR4 expression in the primary lesion frequently had cytomembrane CXCR4-positive
tumours in their LNs. In conclusion, expression of SDF-1a and nuclear CXCR4 predicts LN metastasis in CRCs.
British Journal of Cancer (2008) 98, 1682–1689. doi:10.1038/sj.bjc.6604363 www.bjcancer.com
Published online 29 April 2008
& 2008 Cancer Research UK
Keywords: chemokines; SDF-1a; CXCR4; colorectal cancer; lymph node metastasis
                                                 
Chemokines belong to the small molecular chemoattractive
cytokine family and are classified into four groups (CXC, CXC3,
CC, and C) according to the positions of the four conserved
cysteine residues (Baggiolini et al, 1997; Rollins, 1997). Their
actions are mediated by G-protein-coupled receptors, which are
characterised by a seven-transmembrane-spanning domain.
Stromal cell-derived factor (SDF)-1a, which was originally cloned
from murine bone marrow (Tashiro et al, 1993), is a member (CXC
chemokine ligand 12) of the CXC subfamily and exerts an effect
through its specific receptor CXCR4 (Tachibana et al, 1998;
Zou et al, 1998). The SDF-1a–CXCR4 axis was initially found to be
stimulated by the homing of lymphocytes to inflammatory tissues
and has recently been found to be involved in many areas of
immunology and human development, including organogenesis,
vascularisation, haematopoiesis, and embryogenesis (Murdoch,
2000). Moreover, recent studies have reported that SDF-1a and
CXCR4 may play important roles in cell survival, proliferation,
chemotaxis, migration, and adhesion (Vlahakis et al, 2002; Kayali
et al, 2003; Soriano et al, 2003; Fernandis et al, 2004; Hartmann
et al, 2005), suggesting that the SDF-1a–CXCR4 axis is involved in
tumorigenicity. However, although these biological functions of
SDF-1a and CXCR4 were examined mainly in in vitro studies, the
pathophysiological significance of SDF-1a and CXCR4 in human
disease still remains unclear. Therefore, we examined the
expression of SDF-1a and CXCR4 in colorectal cancers (CRCs)
and their related lymph nodes (LNs), and investigated the
relationship between this expression and clinicopathological
features. In addition, because our immunohistochemical analysis
of CRC cells revealed nuclear expression of CXCR4, which is
normally expressed in the cytomembrane, we also investigated the
presence of CXCR4 protein in the nucleus and its pathophysio-
logical significance.
MATERIALS AND METHODS
Patients and tissue samples
A total of 60 patients with CRC who underwent surgery or
endoscopic resection at Dokkyo University School of Medicine
between 1990 and 2003 were enrolled. Patients with familial
adenomatous polyposis, hereditary nonpolyposis colorectal
cancer, inflammatory bowel disease, or other malignancies were
excluded, as were patients who had received preoperative
treatment such as chemotherapy or radiation therapy. The study
was performed with the approval of the Dokkyo University
Surgical Pathology Committee, and informed consent was
obtained from all patients.
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embedded in paraffin. Multiple haematoxylin-and-eosin-stained
sections of CRC and its related LNs were examined. The following
factors were determined for all patients and lesions: age, gender,
tumour location, tumour size, tumour differentiation, tumour
invasion, LN metastases, and tumour stage. Tumour differentia-
tion and stage were determined according to the WHO and UICC
criteria, respectively. All these clinicopathological features are
summarised in Table 1.
Immunostaining
Immunohistochemical staining for SDF-1a and CXCR4 was
performed as described previously (Fukui et al, 2004). In brief, the
sections (4mm thick) were deparaffinised, rehydrated, placed in
0.01moll
 1 citrate buffer (pH 6.0), and treated by microwave heating
for 10min. The sections were then preincubated with 0.3% H2O2 in
methanol for 20min at room temperature to quench endogenous
peroxidase activity. Subsequently, the sections were immunostained
with an UltraTech Kit (Immunotech, Marseille, France) in accordance
with the manufacturer’s instructions. The sections were pretreated
with 1% bovine serum albumin in phosphate-buffered saline (PBS)
and then incubated with anti-SDF-1a antibody (R&D Systems Inc.,
Minneapolis, MN, USA; dilution 1:50) and anti-CXCR4 antibody (BD
Biosciences Pharmingen, San Diego, CA, USA; dilution 1:20) for 1h
at room temperature. Thereafter, the sections were incubated with
biotinylated secondary antibody for 15min, washed with PBS, and
treated with peroxidase-conjugated streptavidin for 20min. Finally,
the sections were incubated in 3,30-diaminobenzidine tetrahy-
drochloride with 0.05% H2O2 for 3min and then counterstained
with Carazzi’s haematoxylin. Sections of oesophageal cancer that had
been confirmed to overexpress these proteins were used as positive
controls, and antibodies were not applied to negative controls.
Table 1 Clinicopathological features of the patients with colorectal
cancer
Gender
Man 41 (68.3%)
Woman 19 (31.7%)
Age (years, mean±s.d.) 63.8±10.9 (39–88)
Tumour location
Colon 49 (81.7%)
Rectum 11 (18.3%)
Tumour size (cm, mean±s.d.) 4.1±2.0 (0.7–8.7)
Differentiation
Well 26 (43.3%)
Mod 30 (50.0%)
Por 4 (6.7%)
UICC stage
I 10 (16.7%)
II 23 (38.3%)
III 12 (20.0%)
IV 15 (25.0%)
Lymphatic invasion
None 15 (25.0%)
Present 45 (75.0%)
Venous invasion
None 28 (46.7%)
Present 32 (53.3%)
Lymph node metastasis
None 33 (55.0%)
Present 27 (45.0%)
AB
CD
Figure 1 Immunohistochemistry for SDF-1a in the normal colon and in CRC tissues. (A) Weak to negative immunoreactivity is observed in the cytoplasm
of non-neoplastic epithelial cells. (B) Immunoreactivity for SDF-1a is also observed in the lymphoid follicle in the colonic mucosa. (C) Strong type:
immunoreactivity is strongly detected in the cytoplasm of cancer cells. (D) Weak type: immunoreactivity is weakly detected in the cytoplasm of cancer cells.
Immunoreactivity is also observed in the endothelial cells of the tumour stroma. Scale bars¼100mm.
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To examine the pathophysiological role of SDF-1a and CXCR4 in
metastasis, we assessed the immunoreactivity of SDF-1a and
CXCR4 in the invasive front of CRCs and in their related LN
metastases (magnification  200), because the invasive front is a
source of metastasised tumour cells and LNs are the first regions
that metastasised tumour cells colonise.
In the present study, we defined the normal endothelial cells
as an internal control for SDF-1a immunoreactivity. SDF-1a
immunoreactivity was detected in the cytoplasm of CRC cells.
The CRC cells were considered to have strong SDF-1a expression
if their signal was stronger than or equal to that of endothelial
cells in the adjacent normal colonic tissues; otherwise, the CRC
cells were considered to have weak SDF-1a expression. The
CRC samples were classified into a strong group when CRC
cells with strong SDF-1a expression were dominant at the invasive
front of the tumour. Otherwise, we classified them into a weak
group.
CXCR4 immunoreactivity was detected in the cytoplasm and
in the nucleus of CRC cells. Some CRCs showed clear CXCR4
immunoreactivity in the nucleus and a weak signal in the
cytoplasm (nuclear type), whereas others showed no nuclear
immunoreactivity but a diffuse signal in the cytoplasm and at the
plasma membrane (cytomembrane type). Every lesion was
classified as either nuclear or cytomembrane type in accordance
with its dominant immunostaining pattern in its invasive front. On
the other hand, the CRC samples showing no CXCR4 immuno-
reactivity were defined as negative.
Nuclear protein extraction and western blot analysis
A human colorectal cancer cell line, HT29, was maintained in
RPMI 1640 medium (Invitrogen, Grand Island, NY, USA) with 10%
fetal bovine serum (Sigma Chemical Co., St Louis, MO, USA).
Proteins were extracted from these cells and separated into the
nuclear fraction and membrane-cytoplasmic fractions, as de-
scribed previously (Hoshino et al, 2007). In brief, the cells were
mixed with lysis buffer containing 10mM Tris-HCl (pH 7.9), 10mM
KCl, 1.5mM MgCl2,1 m M DTT, 1% Nonidet P-40, and 1 
proteinase inhibitor (Complete Mini; Roche, Mannheim,
Germany). Proteins from the membrane and cytoplasm were
extracted from the supernatants, and the precipitate was
additionally treated with nuclear lysis buffer containing 20mM
Tris-HCl (pH 7.9), 400mM NaCl, 1.5mM MgCl2, 0.2mM EDTA,
1m M DTT, 5% glycerol, and 1  proteinase inhibitor (Complete
Mini; Roche). After centrifugation, the nuclear protein was
extracted from the treated supernatants.
Western blot analysis was carried out as described previously
(Sekikawa et al, 2005). Briefly, protein extract (12.5mg) was
fractionated by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis and transferred to a polyvinylidene difluoride
membrane. The membrane was incubated with primary antibodies
and then with a peroxidase-conjugated secondary antibody.
Proteins were detected by an enhanced chemiluminescence system
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Statistical analysis
The w
2 test was performed to determine correlations among the
various parameters, and Fisher’s exact test was also used, as
necessary. Cumulative survival rate was assessed by the Kaplan–
Meier method and analysed by log-rank test. Multivariate analysis
was performed with the Cox proportional hazards model with
hazard ratios (HRs) and 95% confidence intervals (CIs) to evaluate
independent prognostic factors. Differences at Po0.05 were
considered statistically significant.
RESULTS
Expression of SDF-1a in normal colon and CRC tissues
In normal colorectal epithelium adjacent to the tumour, weak to
negative immunoreactivity of SDF-1a was observed in the
cytoplasm of non-neoplastic cells (Figure 1A). Stromal cell-derived
factor-1a immunoreactivity was also observed in the lymphoid
follicles in the colonic mucosa (Figure 1B).
In the CRC tissues, SDF-1a immunoreactivity was detected in
the cytoplasm of cancer cells and vascular endothelial cells in the
tumour stroma (Figure 1C and D). Thirty-eight (63.3%) of the 60
CRCs showed strong immunoreactivity for SDF-1a at the invasive
front and were classified as strong type. Seventeen CRCs showed
weak to faint SDF-1a immunoreactivity. Five showed no signal and
were subsequently also classified as weak type.
Relationship between SDF-1a expression and
clinicopathological features in CRCs
Tumour stage and prevalence of lymphatic invasion, venous
invasion, and LN metastasis were significantly higher in CRCs
showing strong SDF-1a expression than in those with weak
expression (Table 2). However, none of the other parameters – age,
gender, tumour location, tumour size, or differentiation – had a
significant relationship to SDF-1a expression.
Table 2 Relationship between SDF-1a expression and clinicopatholo-
gical features
SDF-1a expression
Weak
(n¼22)
Strong
(n¼38) P-value
Gender
Man 12 29 0.145
Woman 10 9
Age (years, mean±s.d.) 63.7±10.7 63.9±11.2 0.962
Tumour location
Colon 18 31 0.999
Rectum 4 7
Tumour size (cm, mean±s.d.) 3.6±2.4 4.4±1.8 0.128
Differentiation
Well 12 14
Mod 9 21 0.185
Por 1 3
UICC stage
I8 2
II 10 13 0.0002
III 3 9
IV 1 14
Lymphatic invasion
None 11 4 0.001
Present 11 34
Venous invasion
None 15 13 0.016
Present 7 25
Lymph node metastasis
None 18 15 0.003
Present 4 23
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In the normal colorectal epithelium adjacent to the tumour, weak
immunoreactivity for CXCR4 was generally detected in the
cytoplasm and plasma membrane of non-neoplastic epithelial
cells (Figure 2A).
In the CRC tissues, CXCR4 immunoreactivity was found not
only in cancer cells but also in lymphocytes in the tumour stroma.
Here, we focussed on the immunostaining pattern for CXCR4 in
cancer cells at the invasive fronts of tumours. Forty-seven (78.3%)
of the 60 CRCs were positive for CXCR4 expression at the invasive
front. In 29 (61.7%) of these 47 CXCR4-positive CRCs, CXCR4
immunoreactivity was clearly localised in the nucleus (nuclear
type; Figure 2B). In the remaining 18 cases (38.3%), it was detected
diffusely in the cytoplasm and plasma membrane (cytomembrane
type; Figure 2C).
Localisation of CXCR4 proteins in the CRC cell line
We examined the specificity of CXCR4 immunoreactivity by using
the CRC cell line HT29. CXCR4 immunoreactivity was detected
not only weakly at the plasma membrane but also strongly on the
nucleus strongly (Figure 3A).
Localisation of CXCR4 proteins was also examined in HT29 cells
by western blot analysis. Western blots revealed CXCR4 protein in
not only the cytomembrane fraction but also the nucleus
(Figure 3B).
Relationship between CXCR4 expression and
clinicopathological features in CRCs
CXCR4 expression was significantly positive in CRCs with high
tumour stage and with LN metastasis (Table 3). Additionally,
A B
C
Figure 2 Immunohistochemistry for CXCR4 in the normal colon and in CRC tissues. (A) Weak immunoreactivity is observed in the cytoplasm and
plasma membrane of non-neoplastic epithelium cells. (B) Nuclear type: immunoreactivity is detected in the cytoplasm of cancer cells weakly and in the nuclei
strongly. (C) Cytomembrane type: immunoreactivity is detected in the cytoplasm and plasma membrane of cancer cells. Scale bars¼100mm.
CXCR4
Histone H1
Cytomembrane nucleus
B A
Figure 3 Subcellular localisation of CXCR4 in the CRC cell line HT29. (A) Immunohistochemistry. CXCR4 immunoreactivity is detected not only weakly
at the plasma membrane but also strongly in the nuclei. (B) Western blot analysis. CXCR4 immunoreactivity is detected not only in the cytoplasmic and
membranous (‘cytomembrane’) fraction but also in the nuclear (‘nuclear’) protein fraction from HT29 cells.
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lymphatic invasion than in those without.
We next divided CXCR4-positive CRCs into nuclear and
cytomembrane types and further investigated the importance of
CXCR4 immunostaining patterns (Table 4). Comparison of
nuclear- and cytomembrane-type CXCR4-positive CRCs revealed
that the nuclear-type CRCs were significantly more likely to show
poor differentiation, high tumour stage, and frequent LN
metastasis. In addition, lymphatic invasion tended to be more
frequent in nuclear-type CRCs. Moreover, comparison of CXCR4-
negative and CXCR4 nuclear-type-positive CRCs revealed that
malignant potential, as indicated by tumour stage, lymphatic
invasion, venous invasion, and LN metastasis, was clearly higher in
CXCR4 nuclear-type-positive tumours.
Relationship between SDF-1a and CXCR4 expression in
primary CRCs
CXCR4-positive CRCs showed significantly stronger SDF-1a
expression than did negative ones (Table 5; P¼0.002). However,
among the CXCR4-positive CRCs, SDF-1a expression did not differ
between the nuclear and cytomembrane types.
Expression of SDF-1a and CXCR4 in metastasised tumour
cells in LNs
Twenty-seven CRCs showed metastasis to their related LN. Among
these primary CRCs, 23 (85.2%) had strong expression of SDF-1a.
Twenty-four (88.9%) of the 27 metastasised tumours in LNs
(MTLNs) showed strong expression of SDF-1a. Thus, most of the
CRCs with LN metastases (n¼22, 81.5%) showed strong SDF-1a
expression, not only in the primary lesion but also in their MTLNs
(Figure 4A).
Twenty-six (96.3%) of the 27 primary CRCs with LN metastases
were positive for CXCR4 expression: 20 (74.1%) with nuclear
patterns and 6 (22.2%) with cytomembrane patterns (Figure 5).
Twenty-three (85.2%) of the 27 MTLNs were positive for CXCR4
expression. Sixteen (69.6%) of the MTLNs had CXCR4 immuno-
staining patterns of the cytomembrane type and seven (30.4%)
were of the nuclear type. Interestingly, 11 (55.0%) of the 20
primary CRCs that had nuclear-type CXCR4 immunoreactivity had
cytomembrane-type CXCR4 positivity in their LNs. However, five
Table 3 Comparison of the clinicopathologial features between the
CXCR4-positive and CXCR4-negative CRC patients
Positive
(n¼47)
Negative
(n¼13) P-value
Gender
Man 31 10 0.522
Woman 16 3
Age (years, mean±s.d.) 64.0±10.8 63.2±11.9 0.829
Tumour location
Colon 38 11 0.999
Rectum 9 2
Tumour size (cm, mean±s.d.) 4.3±1.8 3.4±2.8 0.158
Differentiation
Well 20 6
Mod 24 6 0.872
Por 3 1
UICC stage
I3 7
II 18 4 o0.0001
III 11 2
IV 15 0
Lymphatic invasion
None 9 6 0.070
Present 38 7
Venous invasion
None 19 9 0.115
Present 28 4
Lymph node metastasis
None 21 12 0.004
Present 26 1
Table 4 Relationship between CXCR4 immunostaining pattern and
clinicopathological features in patients with CXCR4-positive CRC
Nuclear
(n¼29)
Cytomembrane
(n¼18) P-value
Gender
Man 19 12 0.999
Woman 10 6
Age (years, mean±s.d.) 63.0±11.4 65.6±9.9 0.419
Tumour location
Colon 21 17 0.999
Rectum 8 1
Tumour size (cm,
mean±s.d.)
4.3±1.7 4.2±2.0 0.882
Differentiation
Well 9 11
Mod 17 7 0.028
Por 3 0
UICC stage
I0 3
II 9 9 0.022
III 9 2
IV 11 4
Lymphatic invasion
None 3 6 0.068
Present 26 12
Venous invasion
None 9 10 0.172
Present 20 8
Lymph node metastasis
None 9 12 0.036
Present 20 6
Table 5 Relationship between CXCR4 expression and SDF-1a expression
in primary tumour
CXCR4 positive
Nuclear Cytomembrane Total CXCR4 negative
SDF-1a expression
Weak 7 5 12 10
Strong 22 13 35
a 3
aCXCR4-positive CRCs showed significantly stronger SDF-1a expression than did
negative ones (P¼0.002).
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immunoreactivity had the same CXCR4 immunoreactivity patterns
in their MTLNs. These findings suggest that MTLNs are
significantly more likely to show cytomembrane pattern CXCR4
immunoreactivity even when their primary CRCs show nuclear-
type CXCR4 immunoreactivity (Figure 4B).
Survival analysis
Log-rank statistics showed that lymphatic invasion, LN metastasis,
and disease stage were significant prognostic indicators for overall
patient survival (P¼0.043, 0.0005, and o0.0005, respectively).
There was no significant correlation between prognosis and other
clinicopathological features.
To assess the prognostic significance of SDF-1a and CXCR4
expression, Kaplan–Meier survival curves were constructed. The
prognosis of CRC patients with strong SDF-1a expression was
significantly worse than that of CRC patients with weak SDF-1a
expression (Figure 6A). Patients with CXCR4-positive CRCs also
had significantly worse outcomes than those with CXCR4-negative
ones (Figure 6B). Furthermore, CRC patients with nuclear-type
CXCR4 expression tended to have worse outcomes than those with
cytomembrane-type expression (Figure 6C).
Multivariate analysis by Cox regression and correction for
disease stage, CXCR4 expression, and SDF-1a expression showed
B A
Figure 4 Expression of SDF-1a and CXCR4 in MTLNs. Representative photomicrographs of MTLNs, showing (A) strong SDF-1a expression and (B)
cytomembrane-type CXCR4. Scale bars¼100mm.
Nuclear type Nuclear type
(n=20) (n=7)
(n=6) (n=16)
(n=1) (n=4)
Metastasized tumour 
in lymph node
Cytomembrane type Cytomembrane type
Negative Negative
Primary  tumour
Figure 5 Immunostaining pattern of CXCR4 in primary CRCs and
MTLNs. MTLNs show significant cytomembranous immunoreactivity even
when the primary tumours show nuclear immunoreactivity (n¼27,
P¼0.012).
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Figure 6 Overall survival according to (A) SDF-1a immunoreactivity;
(B) CXCR4 immunoreactivity; and (C) CXCR4 immunostaining pattern in
patients with CRCs (n¼60). Kaplan–Meier survival curves were
constructed and pairwise differences were analysed by log-rank test. Nega,
negative; Cytom, cytomembrane; Nuc, nuclear.
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CI 1.08–6.41, P¼0.033), whereas SDF-1a (HR¼1.46, 95% CI
0.52–4.10, P¼0.475) and CXCR4 expression (HR¼5.08, 95%
CI 0.65–40.0, P¼0.123) were not statistically significant.
DISCUSSION
CXCR4 has been shown experimentally to be crucial for cancer cell
adhesion and/or migration (Kawamata et al, 2003), suggesting the
involvement of CXCR4 in tumour invasion and metastasis.
Supporting such in vitro data, our clinicopathological study
revealed that CXCR4 expression was significantly positive in CRCs
with a high tumour stage and LN metastasis, and patients with
CXCR4-positive CRCs showed a significantly worse outcome than
those in whom CRCs were negative, suggesting that CXCR4 is a
significant prognostic marker in CRC patients.
Interestingly, we found that CRC cells had two distinct
immunostaining patterns for CXCR4: cytomembrane and nuclear
types, similar to those reported in cases of hepatocellular
carcinoma (Shibuta et al, 2002), breast cancer (Kato et al, 2003;
Shim et al, 2006), lung cancer (Spano et al, 2004), and
nasopharyngeal carcinoma (Wang et al, 2005). As CXCR4 is a
transmembrane protein, it was originally believed that its
expression would be detectable at the plasma membrane and in
the cytoplasm, and in contrast, that nuclear CXCR4 expression
would be detected nonspecifically by immunohistochemistry.
However, our initial examination of the localisation of CXCR4 in
CRC cell lines showed that CXCR4 immunoreactivity was
detectable not only in the cytomembrane but also in nuclear
protein fractions, suggesting the specificity of CXCR4 immuno-
reactivity in the nuclei of CRC cells. Of note, CRC patients with
nuclear-type CXCR4 expression showed more frequent LN
metastasis, poor differentiation, and worse outcome than those
with cytomembrane-type expression, suggesting that nuclear
expression of CXCR4 may play a role in the progression of CRC.
Although a few in vitro studies have described SDF-1a
expression in CRC cell lines (Brand et al, 2005; Wendt et al,
2006), ours is the first demonstration that considerable numbers of
human CRC lesions indeed produce SDF-1a. Moreover, it was
important that SDF-1a expression was associated with not only
lymphatic invasion, venous invasion, and LN metastasis but also
survival of CRC patients. In conflict with our present data, a single
study by northern blot preliminarily reported that SDF-1a mRNA
expression was decreased in CRC tissues in comparison with
normal colon tissues (Shibuta et al, 1997). However, we found that
SDF-1a was moderately produced in the lymphoid follicles but
faintly by colorectal epithelial cells in normal colon tissues. Thus,
northern blot analysis of CRC tissues might not compare the SDF-
1a mRNA levels of normal colorectal epithelial cells and CRC cells.
Although CRC tissues also contain SDF-1a-positive stromal cells,
immunohistochemistry clearly demonstrated that the cancerous
cells in more than 50% of CRC samples examined had much
stronger expression of SDF-1a than their neighbouring normal
colonic epithelial cells. Accordingly, as with CXCR4 overexpres-
sion, the SDF-1a–CXCR4 axis appears to play important roles in
the progression of CRC.
One concern is the molecular mechanism of nuclear CXCR4
expression and the pathobiological roles of the SDF-1a–CXCR4
axis in CRC progression. Stromal cell-derived factor-1a stimula-
tion triggers CXCR4 internalisation, involving G-protein-coupled
receptor kinases, followed by the binding of b-arrestin and
subsequently CXCR4 endocytosis (Haribabu et al, 1997; Orsini
et al, 1999; Cheng et al, 2000; Burger et al, 2003). On the other
hand, Zeelenberg et al (2003) showed that endogenous SDF-1a
binds newly synthesised CXCR4 and subsequently inhibits the
translocation of CXCR4 to the cell surface. In these contexts, we
expected that SDF-1a expression might be associated with nuclear
CXCR4 expression in CRC cells, and therefore investigated the
CXCR4 expression pattern in CRC cells that had metastasised to
LNs, as SDF-1a is abundantly produced and furthermore, most
MTLNs showed strong SDF-1a expression there. However,
contrary to expectation, even CRC patients with nuclear patterns
of CXCR4 expression in the primary lesion frequently had
cytomembrane-type CXCR4-positive tumours in the LNs. More-
over, we observed no significant relationships between SDF-1a
expressional intensity and CXCR4 expression pattern in the
primary CRCs. Thus, considering these findings as a whole, it is
difficult to explain the molecular mechanism of nuclear CXCR4
expression in CRC cells in terms of its association with SDF-1a
alone. On the other hand, it is known that hypoxia-inducible
factor-1a (HIF-1a) plays a critical role in CXCR4 expression in the
tumour cells under hypoxic condition (Pouysse ´gur et al, 2006).
Interestingly, Shim et al (2006) have recently reported that HIF-1a
expression is reduced in MTLNs of patients with breast cancer and
moreover that MTLNs showed cytoplasmic immunoreactivity for
CXCR4 expression. Although it is still unclear why immunostain-
ing pattern of CXCR4 in MTLNs is different from that in primary
lesions, SDF-1a and HIF-1a may be possible keys to determine
CXCR4 expression pattern.
In summary, we demonstrated here that both CXCR4 and SDF-
1a expressions are closely associated with LN metastasis and poor
prognosis in patients with CRC. Moreover, we clarified the fact that
CXCR4 is detectable not only at the plasma membrane but also in
the cytoplasm or nucleus of CRC cells, although the molecular
mechanism of nuclear CXCR4 expression remains to be elucidated.
As nuclear CXCR4 expression in the primary CRC may reflect
increased potential for LN metastasis, the pathobiological sig-
nificance of translocated CXCR4 needs to be investigated in future
studies.
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